In the study, researchers proposed using targeted micro RNA therapy to reduce the incidence of secondary cataracts by stopping them before they start developing.
The results of the study, published in Molecular Medicine, provide a “roadmap for potential therapies that control miRNA expression for the prevention of secondary cataracts,” according to the release.
The study was conducted in the University of Dayton’s Center for Tissue Regeneration and Engineering at Dayton, with Panagiotis Tsonis, PhD, biology professor and the center’s director as the principal investigator.
Related Articles on Cataracts:
NV’s New Eyes Now Offers LenSx Laser Cataract Surgery
Ophthalmologist on the Move: Dr. Kevin H. Merkley Joins TX’s UTMB Health Eye Center
